Tags

Type your tag names separated by a space and hit enter

SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.
Pharmacogenomics. 2015; 16(10):1077-88.P

Abstract

AIM

To investigate the association between SOST gene polymorphisms and response to alendronate treatment.

MATERIALS & METHODS

639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of SOST were analyzed. Bone mineral density (BMD), serum ALP and β-CTX levels were measured. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed.

RESULTS

rs1234612 and rs851054 polymorphisms were correlated to baseline lumbar spine BMD (p < 0.05). After 12 months of treatment rs1234612 and rs865429 polymorphisms were correlated to BMD changes at the lumbar spine (p < 0.05) or femoral neck (p < 0.05), respectively.

CONCLUSION

The polymorphisms of SOST are genetic factors affecting bone health and response to alendronate in Chinese postmenopausal women.

Authors+Show Affiliations

Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Metabolic Bone Disease & Genetics Research Unit, Department of Osteoporosis & Bone Diseases, Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University, Shanghai, China.Institute of Endocrinology & Metabolism, Second Xiangya Hospital of Central South University, Changsha, Hunan, China.Department of Endocrinology, Osteoporosis Education Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.Department of Orthopedics, Xijing Hospital, The Fourth Liberation Army University, Xi'an, Shaanxi, China.Department of Endocrinology, Guangdong General Hospital, Guangzhou, Guangdong, China.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.Department of Obstetrics & Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26250343

Citation

Zhou, Pei-ran, et al. "SOST Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women With Osteoporosis." Pharmacogenomics, vol. 16, no. 10, 2015, pp. 1077-88.
Zhou PR, Xu XJ, Zhang ZL, et al. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. Pharmacogenomics. 2015;16(10):1077-88.
Zhou, P. R., Xu, X. J., Zhang, Z. L., Liao, E. Y., Chen, D. C., Liu, J., Wu, W., Jiang, Y., Wang, O., Xia, W. B., Xing, X. P., Xu, L., & Li, M. (2015). SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. Pharmacogenomics, 16(10), 1077-88. https://doi.org/10.2217/pgs.15.76
Zhou PR, et al. SOST Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women With Osteoporosis. Pharmacogenomics. 2015;16(10):1077-88. PubMed PMID: 26250343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis. AU - Zhou,Pei-ran, AU - Xu,Xiao-jie, AU - Zhang,Zhen-lin, AU - Liao,Er-yuan, AU - Chen,De-cai, AU - Liu,Jian, AU - Wu,Wen, AU - Jiang,Yan, AU - Wang,Ou, AU - Xia,Wei-bo, AU - Xing,Xiao-ping, AU - Xu,Ling, AU - Li,Mei, Y1 - 2015/08/07/ PY - 2015/8/8/entrez PY - 2015/8/8/pubmed PY - 2016/6/16/medline KW - SOST gene KW - osteoporosis KW - polymorphisms KW - response to alendronate SP - 1077 EP - 88 JF - Pharmacogenomics JO - Pharmacogenomics VL - 16 IS - 10 N2 - AIM: To investigate the association between SOST gene polymorphisms and response to alendronate treatment. MATERIALS & METHODS: 639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of SOST were analyzed. Bone mineral density (BMD), serum ALP and β-CTX levels were measured. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed. RESULTS: rs1234612 and rs851054 polymorphisms were correlated to baseline lumbar spine BMD (p < 0.05). After 12 months of treatment rs1234612 and rs865429 polymorphisms were correlated to BMD changes at the lumbar spine (p < 0.05) or femoral neck (p < 0.05), respectively. CONCLUSION: The polymorphisms of SOST are genetic factors affecting bone health and response to alendronate in Chinese postmenopausal women. SN - 1744-8042 UR - https://www.unboundmedicine.com/medline/citation/26250343/SOST_polymorphisms_and_response_to_alendronate_treatment_in_postmenopausal_Chinese_women_with_osteoporosis_ L2 - http://www.futuremedicine.com/doi/full/10.2217/pgs.15.76?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -